Genmab and Evaxion on top of the news with Y-mAbs and Cessatech topping the charts

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Last week Genmab announced a USD 1.8 Billion acquisition of ProFoundBio but the stock ended slightly down for the week. Furthermore, Evaxion had positive results for EVX-B1 vaccine with an undisclosed partner, and Acarix sent an application for trading in the United States.

7 of the 21 Danish companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Gubra is now the best-performing Danish healthcare stock year-to-date with a 134% return and Pila Pharma was the best Nordic healthcare investment last week.

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.



Acarix has submitted application for cross-trading at OTCQB in the US (Link)

Ascendis Pharma

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024 (Link)


No news the past week


No news the past week

CS Medica

Rescheduled Q4 2023 Presentation (Link)


No news the past week

Evaxion Biotech

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection (Link)


No news the past week


No news the past week


Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio (Link). Genmab acquire the company for USD 1.8 billion.

Bernstein to 1662 and UBS 2750

Transactions in Connection with Share Buy-back Program (Link)


Resolutions of Gubra’s Annual General Meeting 2024 (Link)

Initiator Pharma

No news the past week

IO Biotech

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer (Link)

Pila Pharma

No news the past week


No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week


No news the past week

Zealand Pharma

A member of the board of directors sold 2,000 shares at DKK 712 corresponding to DKK 1,424,000 (Link)

Y-mAbs Therapeutics

No news the past week


2CUREX AB provides an update on its financial position and current operations (Link)



On average, the Danish biotech and healthcare stocks delivered a negative share price performance of the past week of 0.3%. Pila Pharma was the best stock with a 30% increase although it was without any news and based on a turnover of just SEK 300,000 for the whole week. Evaxion also did very well following the announcement of positive results for EVX-B1 vaccine with an undisclosed partner. The market responded negatively to Genmab’s USD 1.8 billion acquisition of ProFoundBio. Finally, Acarix also fell after they submitted an application for cross-trading in the U.S. that could increase the turnover in the stock.

The best stocks year-to-date continue to be Y-mAbs Therapeutics, Zealand Pharma, and Gubra with 71-134% increases after the first 3 months of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 3.6%.

Overview of share price developments the past week, year-to-date, and last twelve months


In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) rose 0.7% to 61.53. The index was recovering from its all-time low in October of 57.12 but has since been on a downward trajectory. In the past 12 months, the index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 20%.

The index development for Kapital Partner Healthcare Index the past 12 months

The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.

64-84% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

Genetic Analysis AB (84%) conducts research and development in the field of diagnostics, with the main focus on the human microbiome. The technology is based on the company’s research platform and the products are used, for example, for testing and analysis of bacteria and other viruses. 

Moberg Pharma AB (65%)focused on the commercialization of proprietary medicines based on proven substances. The company mainly works in nail fungus, where Moberg Pharma is developing a new external treatment. The company has agreements with commercial partners on site in Europe and Asia, among other places. 

SoftOx Solutions (64%) has developed a self-patented solution based on acetic acid for the treatment of chronic wounds in patients. The solution is used to eliminate infections associated with biofilms, which consist of different clusters of bacteria. Part of the drug development takes place in collaboration with other research institutes.

Sources: Refinitiv Eikon, Cision, Nordnet & company websites


Selected cases

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.

Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Del indlægget på sociale media eller på email.